Solid Tumor Core Panel

This test provides information on 49 genes from a patient’s tumor specimen that may be helpful in guiding cancer treatment. The genes were selected based on actionability of mutations identified in those genes, using currently available evidence from national and international guidelines and literature. Actionability is defined as information a clinician might find useful to aid in diagnosis, prognosis and/or treatment strategy for a patient.^1,2

The addition of tumor mutation burden (TMB) and microsatellite instability (MSI) also enable simultaneous assessment of eligibility for immune checkpoint inhibitors.³ Any significant genomic findings are annotated according to Association for Molecular Pathology (AMP) reporting guidelines. A Quest pathologist will review and validate the results and prepare a report for the treating physician.⁴ 

The Solid Tumor Core Panel was developed for patients who have few or no standard treatment options but is available for any patient with a solid tumor. Clinical situations where this panel may be helpful include the following:

• Metastatic or locally advanced disease at presentation
• Tumors with no actionable mutations found in guideline-recommended testing
• Recurrent or metastatic disease that has progressed through all standard-of-care options
• Certain rare tumor types
• Tumors of unknown primary origin
• Small specimens without sufficient material for all guideline-recommended studies to be completed

The Solid Tumor Core Panel uses next-generation sequencing to detect mutations present in DNA and RNA extracted from formalin-fixed, paraffin embedded (FFPE) tissue sections of solid tumors. The test is designed to detect single nucleotide variants (SNVs) and small insertions/deletions, as well as whole-gene copy number alterations and translocations in a select group of genes. Microsatellite instability and/or tumor mutation burden is also evaluated.

The genes tested include: AKT1, AKT2, ALK, AR, BAP1, BRAF, BRCA1, BRCA2, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, GNA11, GNAQ, HRAS, IDH1, JAK2, KIT, KRAS, MAP2K1, MDM2, MET, MTOR, MYC, MYCN, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PTCH1, PTEN, RET, ROS1, TERT, TMPRSS2, TP53, TSC1, and VHL. 

The genes tested for translocations include: ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, RET, ROS1, and TMPRSS2. 

• Preferred: room-temperature, FFPE tissue block containing 200 mm2 of tumor tissue with ≥20% tumor content
• Minimum: 10 mm2 of tumor tissue with ≥10% tumor content

Please contact our dedicated customer service team at 1.833.773.1441.

To discuss possible germline implications of a test result with a Quest genetic counselor, please call Quest Genomic Client Services at 1.866.GENE.INFO (1.866.436.3463).

On average, results will be completed within 14 days after receipt of the sample in the laboratory. Turnaround time may vary based on delays caused by incomplete orders.